Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Dextroamphetamine
Drug ID BADD_D00636
Description Dextroamphetamine is the dextrorotary enantiomer of amphetamine[A2505]. Dextroamphetamine was approved by the FDA in 2001 for the treatment of attention deficit hyperactivity disorder[L6010,Label].
Indications and Usage Dextroamphetamine is indicated for the treatment of attention deficit hyperactivity disorder (ADHD).[Label]
Marketing Status approved; illicit
ATC Code N06BA02
DrugBank ID DB01576
KEGG ID D03740
MeSH ID D003913
PubChem ID 5826
TTD Drug ID D0T3LF
NDC Product Code 68968-0215; 72162-2043; 68968-0220; 68968-0210; 68968-0205; 27808-085
UNII TZ47U051FI
Synonyms Dextroamphetamine | Dexamphetamine | Dexamfetamine | dextro-Amphetamine | dextro Amphetamine | d-Amphetamine | d Amphetamine | Dexedrine | DextroStat | Oxydess | Curban | Dextroamphetamine Sulfate | Sulfate, Dextroamphetamine | Dextro-Amphetamine Sulfate | Dextro Amphetamine Sulfate | d-Amphetamine Sulfate | d Amphetamine Sulfate
Chemical Information
Molecular Formula C9H13N
CAS Registry Number 51-64-9
SMILES CC(CC1=CC=CC=C1)N
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Suicidal ideation19.12.01.003--
Syncope02.11.04.015; 24.06.02.012; 17.02.04.008--
Tachycardia02.03.02.007--Not Available
Thinking abnormal19.10.03.001; 17.02.05.023--Not Available
Tic19.11.04.001; 17.02.05.024--Not Available
Tourette's disorder17.19.02.001; 03.10.01.001; 19.11.04.002--Not Available
Tremor17.01.06.002--
Urinary hesitation20.02.02.0090.001530%Not Available
Urticaria23.04.02.001; 10.01.06.0010.001530%
Vision blurred17.17.01.010; 06.02.06.007--
Visual impairment06.02.10.013--Not Available
Vomiting07.01.07.0030.001755%
Weight decreased13.15.01.005--
Withdrawal syndrome19.07.06.023; 08.06.02.012--Not Available
Mental status changes19.07.01.001--Not Available
Coronary artery dissection12.02.01.035; 24.02.02.001; 02.02.01.0040.000450%Not Available
Energy increased08.01.03.017--Not Available
Emotional distress19.04.02.008--Not Available
Sudden cardiac death08.04.01.008; 02.03.04.016--Not Available
Self-injurious ideation19.12.01.007--Not Available
Affect lability19.04.01.001--Not Available
Paraesthesia oral07.05.05.035; 17.02.06.008--Not Available
Cognitive disorder19.21.02.001; 17.03.03.003--
Adverse event08.06.01.0100.001755%Not Available
Eye movement disorder17.02.05.025; 06.05.02.008--Not Available
Impulse-control disorder19.18.01.002--Not Available
Libido disorder19.08.03.004; 21.03.02.006--Not Available
Abnormal behaviour19.01.01.0010.001530%Not Available
Decreased appetite14.03.01.005; 08.01.09.028--
Erectile dysfunction21.03.01.007; 19.08.04.001--
The 4th Page    First    Pre   4 5    Next   Last    Total 5 Pages